logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HR+ breast cancer: CTCs at 5 years postdiagnosis predict late recurrence

A peripheral blood-based biomarker may be used to stratify risk and guide therapy.